HEALTH SCIENCES ACQUISITIONS CORP 2 HSAQ 深 滬
等待開盤 12-19 09:30:00 美东时间
13.31
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 13.31
- 總市值 1.49亿
- 52周最高 13.80
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 9.41
- 委 比 0.00%
- 總股本 1121.21万
- 歷史最高 14.66
- 量 比 0
- 振 幅 0.00%
- 歷史最低 9.41
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
Gain Therapeutics announces a virtual KOL event on January 6, 2026, at 10 a.m. EST, focusing on GCase substrates in Parkinson’s Disease. Key speakers include Roy Alcalay, M.D., and Peter Lansbury, Ph.D., who will discuss biomarker data from the Phase 1b study of GT-02287, a potential disease-modifying therapy. GT-02287 is an allosteric enzyme modulator targeting GCase dysfunction in PD. The event will include a Q&A session and provide insights in...
12-18 21:05
Nektar Reports Phase 2 Results for Hair Loss Treatment, Misses Initial Stat Target
Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced topline results from the 36-week induction treatment period of the Phase 2b
12-16 20:33
OneMedNet Reports Strong Momentum and Industry Excitement at RSNA
OneMedNet Corporation demonstrated strong engagement and commercial success at RSNA 2025, with healthcare providers and life sciences companies showing significant interest in its iRWD™ platform powered by Palantir Foundry. The platform provides high-quality, regulatory-grade Real-World Data (RWD) through efficient deployment and advanced AI capabilities, enabling faster research and innovation. The company highlighted its ability to meet the nee...
12-10 13:50
Hawkins, Inc. Expands in Texas with Acquisition of Redbird Chemical, Inc.
Hawkins, Inc. has completed the acquisition of Redbird Chemical, Inc.'s assets to expand its operations in eastern Texas, targeting growth in the water treatment and industrial markets. CEO Patrick H. Hawkins emphasized the strategic importance of this acquisition, leveraging the industrial base in Texas to accelerate growth in the southern region. He also highlighted Redbird's strong local connections and expressed excitement for the combined gr...
12-03 13:44
Rasmussen University Launches Radiologic Technology Program at its Central Pasco Campus
Offering to help meet the growing need for skilled Radiologic Technologists in the Tampa Bay area TAMPA BAY, Fla., Nov. 25, 2025 /PRNewswire/ -- Rasmussen University today announced the laun...
11-25 22:05
Bayer Says New Daily Pill Cuts Risk of Repeat Stroke Without Extra Bleeding Risk
Bayer today announced positive topline results from the global Phase III study OCEANIC-STROKE, with its investigational, once daily, oral FXIa inhibitor asundexian. The study met its primary efficacy and safety
11-24 16:04
Why hedge funds hire psychologists to keep traders from burning out
In the high-pressure world of the largest hedge funds, competition is constant -- not just between firms, but within their own trading teams. That intensity has given rise to specialists like psycholo...
11-17 04:05
Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight
Profound Medical Corp. has regained exclusive distribution rights for its TULSA-PRO® system in Canada from Knight Therapeutics Inc. through a one-time payment of $90,000 CAD and a 5% royalty on Canadian sales for 15 years. The TULSA-PRO system, used for treating prostate cancer and benign prostatic hyperplasia (BPH), is an AI-powered, MRI-guided technology that ablates prostate tissue without surgery or radiation. Profound plans to expand the pro...
11-10 21:30
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments
Arcutis Biotherapeutics, Inc. launches the "Free to Be Me" campaign featuring Tori Spelling and her daughter Stella to raise awareness about inflammatory skin diseases like eczema and seborrheic dermatitis. ZORYVE® (roflumilast), the #1 prescribed topical therapy, helps manage these conditions effectively. Tori shares her family's journey of managing skin health with ZORYVE, highlighting its benefits for long-term treatment. Backed by clinical st...
10-30 13:15
Earnings Scheduled For October 22, 2025
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is estimated to repor...
10-22 16:32
